רפלגל
Country: Israel
Language: Hebrew
Source: Ministry of Health
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
AGALSIDASE ALFA
Available from:
TAKEDA ISRAEL LTD
ATC code:
A16AB03
Pharmaceutical form:
תרכיז להכנת תמיסה לאינפוזיה
Composition:
AGALSIDASE ALFA 1 MG/ML
Administration route:
תוך-ורידי
Prescription type:
מרשם נדרש
Manufactured by:
SHIRE HUMAN GENETIC THERAPIES INC., USA
Therapeutic group:
AGALSIDASE ALFA
Therapeutic area:
AGALSIDASE ALFA
Therapeutic indications:
Replagal is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (alfa-galactosidase A deficiency).
Authorization date:
2021-11-30
